Collegium Pharmaceutical Inc
NASDAQ:COLL

Watchlist Manager
Collegium Pharmaceutical Inc Logo
Collegium Pharmaceutical Inc
NASDAQ:COLL
Watchlist
Price: 26.79 USD 0.04% Market Closed
Market Cap: 860.8m USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+47%
Revenue
Forecast
+11%
Operating Income
Forecast
N/A
Net Income
Forecast
N/A

Wall Street
Price Targets

COLL Price Targets Summary
Collegium Pharmaceutical Inc

Wall Street analysts forecast COLL stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for COLL is 43.66 USD with a low forecast of 36.36 USD and a high forecast of 52.5 USD.

COLL Lowest Forecast
Wall Street Target
36.36 USD
36% Upside
COLL Average Forecast
Wall Street Target
43.66 USD
63% Upside
COLL Highest Forecast
Wall Street Target
52.5 USD
96% Upside
Lowest
Price Target
36.36 USD
36% Upside
Average
Price Target
43.66 USD
63% Upside
Highest
Price Target
52.5 USD
96% Upside
Collegium Pharmaceutical Inc Competitors:
Price Targets
RAPP
Rapport Therapeutics Inc
236% Upside
S
GPCR
Structure Therapeutics Inc
244% Upside
P
300363
Porton Pharma Solutions Ltd
49% Upside
SNDL
Sundial Growers Inc
140% Upside
RAPP
Rapport Therapeutics Inc
236% Upside
S
GPCR
Structure Therapeutics Inc
244% Upside
P
300363
Porton Pharma Solutions Ltd
49% Upside
SNDL
Sundial Growers Inc
140% Upside
002603
Shijiazhuang Yiling Pharmaceutical Co Ltd
51% Upside
JNJ
Johnson & Johnson
13% Upside
ZTS
Zoetis Inc
35% Upside
PBH
Prestige Consumer Healthcare Inc
13% Upside

Revenue
Forecast

Revenue Estimate
Collegium Pharmaceutical Inc

For the last 8 years the compound annual growth rate for Collegium Pharmaceutical Inc's revenue is 110%. The projected CAGR for the next 3 years is 5%.

110%
Past Growth
5%
Estimated Growth
Estimates Accuracy
-2%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Collegium Pharmaceutical Inc

The compound annual growth rate of Collegium Pharmaceutical Inc's operating income for the next 3 years is 30%.

N/A
Past Growth
30%
Estimated Growth
Estimates Accuracy
-4%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Collegium Pharmaceutical Inc

The compound annual growth rate of Collegium Pharmaceutical Inc's net income for the next 3 years is 44%.

N/A
Past Growth
44%
Estimated Growth
Estimates Accuracy
-27%
Average Miss
What are analyst estimates?

See Also

Summary
COLL intrinsic value, competitors valuation, and company profile.
DCF Valuation
COLL stock valuation using Discount Cash Flow valuation method.
Relative Valuation
COLL stock valuation using valuation multiples.
Wall Street Estimates
COLL price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
COLL stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is COLL's stock price target?
Price Target
43.66 USD

According to Wall Street analysts, the average 1-year price target for COLL is 43.66 USD with a low forecast of 36.36 USD and a high forecast of 52.5 USD.

What is Collegium Pharmaceutical Inc's Revenue forecast?
Projected CAGR
5%

For the last 8 years the compound annual growth rate for Collegium Pharmaceutical Inc's revenue is 110%. The projected CAGR for the next 3 years is 5%.

What is Collegium Pharmaceutical Inc's Operating Income forecast?
Projected CAGR
30%

The compound annual growth rate of Collegium Pharmaceutical Inc's operating income for the next 3 years is 30%.

What is Collegium Pharmaceutical Inc's Net Income forecast?
Projected CAGR
44%

The compound annual growth rate of Collegium Pharmaceutical Inc's net income for the next 3 years is 44%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 249,800+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.